You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
High‐powered percutaneous microwave ablation of stage I medically inoperable non‐small cell lung cancer: A preliminary study
Contributor:
Liu, Howard;
Steinke, Karin
imprint:
Wiley, 2013
Published in:Journal of Medical Imaging and Radiation Oncology
Language:
English
DOI:
10.1111/1754-9485.12068
ISSN:
1754-9477;
1754-9485
Origination:
Footnote:
Description:
<jats:title>Abstract</jats:title><jats:sec><jats:title>Purpose</jats:title><jats:p>To retrospectively evaluate the feasibility and outcome of using high‐powered percutaneous microwave ablation (<jats:styled-content style="fixed-case">MWA</jats:styled-content>) in treating medically inoperable early stage non‐small cell lung cancer.</jats:p></jats:sec><jats:sec><jats:title>Materials and Methods</jats:title><jats:p>From <jats:styled-content style="fixed-case">N</jats:styled-content>ovember 2010 to <jats:styled-content style="fixed-case">J</jats:styled-content>une 2012, 15 patients underwent <jats:styled-content style="fixed-case">CT</jats:styled-content>‐guided <jats:styled-content style="fixed-case">MWA</jats:styled-content> of 15 tumours in 16 sessions. One patient had a second ablation session for local tumour progression. Each tumour had a diameter of 40 mm or less (median 24 mm). Treatment outcome was evaluated using modified response evaluation criteria in solid tumours criteria based on follow‐up contrast‐enhanced <jats:styled-content style="fixed-case">CT</jats:styled-content> studies and 18‐<jats:styled-content style="fixed-case">F</jats:styled-content> fluorodeoxyglucose positron emission tomography scans.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Thirty‐three ablation cycles of 15 tumours were performed in 16 sessions (2.1 per session), with a median duration of 2.5 min per ablation. Treatment was completed in all cases with no 30‐day mortality. At a median follow‐up period of 1 year, local progression was identified following 5/16 (31%) ablation sessions. Eleven out of 16 (69%) of <jats:styled-content style="fixed-case">MWA</jats:styled-content>s had shown local treatment response, with 9/11 displaying complete response and 2/11 displaying partial response. Local progression on follow up was predominantly seen in pleural‐based tumours that were greater than 30 mm in longest axial diameter (4/5 cases). The main adverse event was a pneumothorax, which occurred in 10/16 (63%) of procedures, but a chest tube was only required in 2/16 (13%) cases.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Percutaneous <jats:styled-content style="fixed-case">MWA</jats:styled-content> in early stage non‐small cell lung cancer is well tolerated and has promising midterm outcomes.</jats:p></jats:sec>